Vendor, Cambridge, MA
Matrisome Bio, Inc.
UEI DWR8LNQUCJR8, CAGE 07E56
1 award and -$54,960 obligated between September 10, 2026 and September 10, 2026, 100% under full and open competition, against 55.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$54,960 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00039Definitive Contract, September 10, 2026, Full and Open Competition After Exclusion of Sources, 55 offers | NIH NCINational Institutes of Health | Novel Theranostic Radioligands Targeting Disease-Specific Extracellular Matrix Components Specific to Tumor and Metastatic Lesions in PatienNAICS 541715, PSC AN12 | -$54,960 |
- Places of performance
- Massachusetts
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards